Increasing empagliflozin dose provides significant clinical benefits in type 2 diabetes: Study Medha Baranwal18 Aug 2022 7:30 PM ISTJapan: Switching from low-dose to high-dose SGLT2 inhibitor empagliflozin provides significant clinical benefits in patients with type 2 diabetes...
Increased dose of Empagliflozin may improve Glycemic control in T2 Diabetes patients Dr.Niharika Harsha B21 July 2022 7:30 PM ISTResearchers have found in a recent study that increasing the dose of Empagliflozin in Patients with Type 2 Diabetes significantly improved certain...
Add on Empagliflozin to automated insulin delivery improves glycemic control in type 1 diabetes Dr. Hiral patel19 July 2022 11:00 AM ISTUSA: A new study showed that the use of empagliflozin as an adjunct to automated insulin delivery (AID) improved glycemic management in adults with...
Zydus Lifesciences bags USFDA approval for Empagliflozin, Metformin Hydrochloride Tablets Ruchika Sharma11 July 2022 12:23 PM ISTThe drug will be manufactured at the group’s formulation facility at SEZ, Ahmedabad, India.
Empagliflozin may reduce serum uric acid in HF patients, lower mortality risk: EMPEROR-reduced trial Medha Baranwal10 July 2022 8:45 PM ISTGermany: In patients with heart failure, hyperuricemia is a common comorbidity and is an independent predictor of advanced disease severity and...
Early empagliflozin initiation induces diuresis in decompensated HF without worsening kidney function Medha Baranwal2 July 2022 12:45 PM ISTGermany: A recent study in Circulation revealed that in patients with acute decompensated heart failure, early empagliflozin addition to standard...
Empagliflozin improves symptoms, reduces hospitalization in HF patients: EMPEROR-preserved Trial Dr.Niharika Harsha B30 Jun 2022 7:30 PM ISTResearchers have found in EMPEROR-preserved trial that in heart failure patients symptoms were improved, primary outcomes were reduced and...
Empagliflozin effectively regulates Serum potassium in Heart Failure, study Dr. Hiral patel24 Jun 2022 7:30 PM ISTFrance: Empagliflozin (anti-diabetic medication) reduced the incidence of hyperkalemia without a substantial increase in hypokalemia in patients with...
Empagliflozin may decrease risk of kidney stones in people with diabetes Dr. Kamal Kant Kohli15 Jun 2022 9:15 AM ISTThe diabetes drug empagliflozin may decrease the risk of kidney stones in patients with type 2 diabetes, according to a new study presented Sunday,...
Empagliflozin may decrease risk of kidney stones in diabetics Dr. Nandita Mohan14 Jun 2022 10:00 AM ISTWe all know that Empagliflozin is the drug used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in...
All SGLT-2 inhibitors found promising for diabetes management in Indian settings: JAPI Medha Baranwal11 Jun 2022 11:30 AM ISTMaharashtra: SGLT2 Inhibitors could be considered as an add-on to all antidiabetic agents currently used for diabetes management in the Indian...
Boehringer Ingelheim's empagliflozin gets CDSCO nod for heart failure with preserved ejection fraction Medical Dialogues Bureau19 May 2022 4:19 PM ISTNew Delhi: Boehringer Ingelheim, one of the world's leading, research-driven pharmaceutical companies, has received approval from the Central Drugs...
